Author Archives: Janet Stewart, MSc

Lack of Hospitals and Care Providers, Higher Black Populations Mark Areas of Low Therapy Reliance in US

Adherence among lupus patients to hydroxychloroquine (HCQ), the backbone of disease therapy, is suboptimal overall but particularly poor among those on Medicaid who live in areas with fewer hospitals, larger African-American populations, and with a shortage of health professionals. These results were reported at the 2017 American College of Rheumatology Annual…

Amgen’s AMG 811 Fails to Improve Lupus Outcomes in Phase 1 Trial

Patients with systemic lupus erythematosus (SLE) with or without lupus nephritis (LN) showed no clinical benefit when treated with Amgen‘s investigative anti-interferon-gamma antibody, AMG 811, in a Phase 1b  (NCT00818948) clinical trial. Some indicators of the disease dropped in response to the treatment, but less so in…